Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Network connectivity and inhibitory control under atomoxetine challenge
2013-002386-18Phase 4Terminated
- Sponsor
- Clinical Trials Center Aachen
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of atomoxetine in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Clinical Trials Center Aachen. Primary endpoint: Change in DMN connectivity and fMRI BOLD response and relation to cognitive performance. Started Nov 2015; status: terminated.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2013-002386-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002386-18.